Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy

Antiviral Research

Volumn 127, Issue , 2016, Pages 10-19

  Watanabe, Satoru ^a   Chan, Kitti Wing Ki ^a   Dow, Geoffrey ^b   Ooi, Eng Eong ^a   Low, Jenny G ^c   Vasudevan, Subhash G ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b 60 Pharmaceuticals LLC   (United States)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

AG129 mouse model; Antiviral; Celgosivir; Dengue virus; Viremia reduction

Indexed keywords

CASTANOSPERMINE 6 BUTYRATE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ALPHA GLUCOSIDASE; ANTIVIRUS AGENT; CYTOKINE; ENZYME INHIBITOR; GLUCOSIDASE I; INDOLIZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERO CELL LINE; VIRUS LOAD; ANIMAL; BLOOD; CELL LINE; CHLOROCEBUS AETHIOPS; CLASSIFICATION; DENGUE VIRUS; DISEASE MODEL; DRUG EFFECTS; HAMSTER; HUMAN; IN VITRO STUDY; ISOLATION AND PURIFICATION; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; VIREMIA; VIROLOGY;

ALPHA-GLUCOSIDASES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; CYTOKINES; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; IN VITRO TECHNIQUES; INDOLIZINES; MICE; REAL-TIME POLYMERASE CHAIN REACTION; SEROGROUP; VERO CELLS; VIRAL LOAD; VIREMIA;

EID: 84955113692     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.12.008     Document Type: Article

References (29)

1. S. Bhatt, P.W. Gething, O.J. Brady, J.P. Messina, A.W. Farlow, C.L. Moyes, J.M. Drake, J.S. Brownstein, A.G. Hoen, O. Sankoh, M.F. Myers, D.B. George, T. Jaenisch, G.R. Wint, C.P. Simmons, T.W. Scott, J.J. Farrar, and S.I. Hay The global distribution and burden of dengue Nature 496 2013 504 507
2. M. Carocci, S.M. Hinshaw, M.A. Rodgers, V.A. Villareal, D.J. Burri, R. Pilankatta, N.P. Maharaj, M.U. Gack, E.J. Stavale, K.L. Warfield, and P.L. Yang The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication Antimicrob. agents Chemother. 59 2015 85 95
3. J. Chang, W. Schul, T.D. Butters, A. Yip, B. Liu, A. Goh, S.B. Lakshminarayana, D. Alonzi, G. Reinkensmeier, X. Pan, X. Qu, J.M. Weidner, L. Wang, W. Yu, N. Borune, M.A. Kinch, J.E. Rayahin, R. Moriarty, X. Xu, P.Y. Shi, J.T. Guo, and T.M. Block Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo Antivir. Res. 89 2011 26 34
4. Y.L. Chen, N. Abdul Ghafar, R. Karuna, Y. Fu, S.P. Lim, W. Schul, F. Gu, M. Herve, F. Yokohama, G. Wang, D. Cerny, K. Fink, F. Blasco, and P.Y. Shi Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir J. virol. 88 2014 1740 1747
5. J. Desmyter, J.L. Melnick, and W.E. Rawls Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero) J. virol. 2 1968 955 961
6. H.T. Duyen, T.V. Ngoc, T. Ha do, V.T. Hang, N.T. Kieu, P.R. Young, J.J. Farrar, C.P. Simmons, M. Wolbers, and B.A. Wills Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status J. Infect. Dis. 203 2011 1292 1300
7. J.E. Fraser, S. Watanabe, C. Wang, W.K. Chan, B. Maher, A. Lopez-Denman, C. Hick, K.M. Wagstaff, J.M. Mackenzie, P.M. Sexton, S.G. Vasudevan, and D.A. Jans A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection J. Infect. Dis. 210 2014 1780 1791
8. D.J. Gubler Dengue/dengue haemorrhagic fever: history and current status Novartis Found. Symp. 277 2006 3 16 discussion 16-22, 71-13, 251-253
9. S.B. Halstead Dengue Lancet 370 2007 1644 1652
10. H.H. Houng, D. Hritz, and N. Kanesa-Thasan Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3'-noncoding sequence J. virol. methods 86 2000 1 11
11. T.H. Keller, Y.L. Chen, J.E. Knox, S.P. Lim, N.L. Ma, S.J. Patel, A. Sampath, Q.Y. Wang, Z. Yin, and S.G. Vasudevan Finding new medicines for flaviviral targets Novartis Found. Symp. 277 2006 102 114 discussion 114-109, 251-103
12. J.G. Low, E.E. Ooi, T. Tolfvenstam, Y.S. Leo, M.L. Hibberd, L.C. Ng, Y.L. Lai, G.S. Yap, C.S. Li, S.G. Vasudevan, and A. Ong Early Dengue Infection and Outcome Study (EDEN) - Study Design and Preliminary Findings 35 2006 Annals of the Academy of Medicine Singapore 783 789
13. J.G. Low, C. Sung, L. Wijaya, Y. Wei, A.P. Rathore, S. Watanabe, B.H. Tan, L. Toh, L.T. Chua, Y. Hou, A. Chow, S. Howe, W.K. Chan, K.H. Tan, J.S. Chung, B.P. Cherng, D.C. Lye, P.A. Tambayah, L.C. Ng, J. Connolly, M.L. Hibberd, Y.S. Leo, Y.B. Cheung, E.E. Ooi, and S.G. Vasudevan Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial Lancet. Infect. Dis. 14 2014 706 715
14. M.R. MacDonald, E.S. Machlin, O.R. Albin, and D.E. Levy The zinc finger antiviral protein acts synergistically with an interferon-induced factor for maximal activity against alphaviruses J. virol. 81 2007 13509 13518
15. A. Mehta, N. Zitzmann, P.M. Rudd, T.M. Block, and R.A. Dwek Alpha-glucosidase inhibitors as potential broad based anti-viral agents FEBS Lett. 430 1998 17 22
16. E. Navarro-Sanchez, R. Altmeyer, A. Amara, O. Schwartz, F. Fieschi, J.L. Virelizier, F. Arenzana-Seisdedos, and P. Despres Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses EMBO Rep. 4 2003 723 728
17. N.M. Nguyen, C.N. Tran, L.K. Phung, K.T. Duong, A. Huynh Hle, J. Farrar, Q.T. Nguyen, H.T. Tran, C.V. Nguyen, L. Merson, L.T. Hoang, M.L. Hibberd, P.P. Aw, A. Wilm, N. Nagarajan, D.T. Nguyen, M.P. Pham, T.T. Nguyen, H. Javanbakht, K. Klumpp, J. Hammond, R. Petric, M. Wolbers, C.T. Nguyen, and C.P. Simmons A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients J. Infect. Dis. 207 2013 1442 1450
18. S.T. Perry, M.D. Buck, E.M. Plummer, R.A. Penmasta, H. Batra, E.J. Stavale, K.L. Warfield, R.A. Dwek, T.D. Butters, D.S. Alonzi, S.M. Lada, K. King, B. Klose, U. Ramstedt, and S. Shresta An iminosugar with potent inhibition of dengue virus infection in vivo Antivir. Res. 98 2013 35 43
19. A.P. Rathore, P.N. Paradkar, S. Watanabe, K.H. Tan, C. Sung, J.E. Connolly, J. Low, E.E. Ooi, and S.G. Vasudevan Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model Antivir. Res. 92 2011 453 460
20. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited. FASEB journal official Publ. Fed. Am. Soc. Exp. Biol. 22 2008 659 661
21. W. Schul, W. Liu, H.Y. Xu, M. Flamand, and S.G. Vasudevan A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs J. Infect. Dis. 195 2007 665 674
22. C.P. Simmons, J.J. Farrar, V. Nguyen v, and B. Wills Dengue N. Engl. J. Med. 366 2012 1423 1432
23. V. Tricou, N.N. Minh, J. Farrar, H.T. Tran, and C.P. Simmons Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue PLoS negl. Trop. Dis. 5 2011 e1309
24. V. Tricou, N.N. Minh, T.P. Van, S.J. Lee, J. Farrar, B. Wills, H.T. Tran, and C.P. Simmons A randomized controlled trial of chloroquine for the treatment of dengue in vietnamese adults PLoS negl. Trop. Dis. 4 2010 e785
25. S. Watanabe, K.W. Chan, J. Wang, L. Rivino, S.M. Lok, and S.G. Vasudevan Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice J. virol. 89 2015 5847 5861
26. S. Watanabe, A.P. Rathore, C. Sung, F. Lu, Y.M. Khoo, J. Connolly, J. Low, E.E. Ooi, H.S. Lee, and S.G. Vasudevan Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial Antivir. Res. 96 2012 32 35
27. S. Watanabe, K.H. Tan, A.P. Rathore, K. Rozen-Gagnon, W. Shuai, C. Ruedl, and S.G. Vasudevan The magnitude of dengue virus NS1 protein secretion is strain dependent and does not correlate with severe pathologies in the mouse infection model J. virol. 86 2012 5508 5514
28. L.E. Yauch, R.M. Zellweger, M.F. Kotturi, A. Qutubuddin, J. Sidney, B. Peters, T.R. Prestwood, A. Sette, and S. Shresta A protective role for dengue virus-specific CD8+ T cells J. Immunol. 182 2009 4865 4873
29. Z. Yin, Y.L. Chen, W. Schul, Q.Y. Wang, F. Gu, J. Duraiswamy, R.R. Kondreddi, P. Niyomrattanakit, S.B. Lakshminarayana, A. Goh, H.Y. Xu, W. Liu, B. Liu, J.Y. Lim, C.Y. Ng, M. Qing, C.C. Lim, A. Yip, G. Wang, W.L. Chan, H.P. Tan, K. Lin, B. Zhang, G. Zou, K.A. Bernard, C. Garrett, K. Beltz, M. Dong, M. Weaver, H. He, A. Pichota, V. Dartois, T.H. Keller, and P.Y. Shi An adenosine nucleoside inhibitor of dengue virus Proc. Natl. Acad. Sci. U. S. A. 106 2009 20435 20439